»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
¾È°ú ÀǾàǰ ½ÃÀå - Á¶»ç ¹üÀ§
TMRÀÇ Á¶»ç º¸°í¼ '¼¼°èÀÇ ¾È°ú ÀǾàǰ ½ÃÀå'Àº 2025-2035³â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ÁöÇ¥¿¡ ´ëÇÑ °¡Ä¡ ÀÖ´Â ÀλçÀÌÆ®¸¦ ¾ò±â À§ÇØ °ú°Å ¹× ÇöÀçÀÇ ¼ºÀå µ¿Çâ°ú ±âȸ¸¦ ¿¬±¸ÇÕ´Ï´Ù. 2025³â ±âÁØ ¿¬µµ, 2035³â ¿¹Ãø¿¬µµ·Î 2025-2035³â ¼¼°èÀÇ ¾È°ú ÀǾàǰ ½ÃÀå ¼öÀͰú ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ 2025-2035³â ¼¼°èÀÇ ¾È°ú ÀǾàǰ ½ÃÀå ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)µµ Á¦°øÇÕ´Ï´Ù.
º» º¸°í¼´Â ±¤¹üÀ§ÇÑ Á¶»ç¸¦ °ÅÃÄ ÀÛ¼ºµÇ¾ú½À´Ï´Ù. 1Â÷ Á¶»ç¿¡¼´Â KOL(Key Opinion Leader), ¾÷°è ¸®´õ, ÀÇ°ß Çü¼ºÀÚµé°ú ÀÎÅͺ並 ½Ç½ÃÇß½À´Ï´Ù. 2Â÷ ¿¬±¸´Â ÁÖ¿ä ¾÷üµéÀÇ Á¦Ç° ¹®Çå, ¿¬Â÷ º¸°í¼, º¸µµ ÀÚ·á ¹× °ü·Ã ¹®¼¸¦ ÂüÁ¶ÇÏ¿© ¾È°ú ÀǾàǰ ½ÃÀåÀ» ÆÄ¾ÇÇß½À´Ï´Ù.
½ÃÀå ÇöȲ
½ÃÀå ¸ÅÃâ(2024³â)
354¾ï ´Þ·¯
½ÃÀå ¸ÅÃâ(2035³â)
679¾ï ´Þ·¯
CAGR
6.1%
º» º¸°í¼´Â ¼¼°èÀÇ ¾È°ú ÀǾàǰ ½ÃÀå °æÀï ±¸µµ¸¦ Á¶»çÇß½À´Ï´Ù. ¼¼°èÀÇ ¾È°ú ÀǾàǰ ½ÃÀå¿¡¼ Ȱµ¿ÇÏ´Â ÁÖ¿ä ¾÷üµéÀ» ½Äº°Çϰí, °¢ ¾÷ü¸¦ ´Ù¾çÇÑ ¼Ó¼º Ãø¸é¿¡¼ ÇÁ·ÎÆÄÀϸµÇß½À´Ï´Ù. ±â¾÷ °³¿ä, À繫 ÇöȲ, ÃÖ±Ù µ¿Çâ, SWOT ºÐ¼®Àº º» º¸°í¼¿¡¼ ÇÁ·ÎÆÄÀϸµµÈ ¼¼°èÀÇ ¾È°ú ÀǾàǰ ½ÃÀå Âü¿© ±â¾÷ ¼Ó¼ºÀÔ´Ï´Ù.
¼¼°èÀÇ ¾È°ú ÀǾàǰ ½ÃÀå º¸°í¼¿¡¼ ´Ù·ç´Â ÁÖ¿ä Áú¹®
¼¼°èÀÇ ¾È°ú ÀǾàǰ ½ÃÀå ºñÁî´Ï½º ±âȸ´Â ¹«¾ùÀΰ¡?
½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎ, ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ, ±âȸ, À§ÇùÀº ¹«¾ùÀΰ¡?
¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÏ´Â Áö¿ª ½ÃÀåÀº ¾îµðÀΰ¡?
2035³â ¼¼°è¿¡¼ °¡Àå ³ôÀº ¼öÀÍÀ» ¿Ã¸± °ÍÀ¸·Î ¿¹»óµÇ´Â ºÎ¹®Àº ¹«¾ùÀΰ¡?
¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ºÎ¹®Àº ¹«¾ùÀΰ¡?
¼¼°è ½ÃÀå¿¡¼ »ç¾÷ Àü°³ÇÏ´Â °¢ ±â¾÷ ½ÃÀå Æ÷Áö¼ÇÀº ¹«¾ùÀΰ¡?
¾È°ú ÀǾàǰ ½ÃÀå - Á¶»ç ¸ñÀû ¹× Á¶»ç ¹æ¹ý
º» Á¶»ç º¸°í¼´Â ¼¼°èÀÇ ¾È°ú ÀǾàǰ ½ÃÀå¿¡ ´ëÇØ ¿¬±¸ ¹× ºÐ¼®ÇÑ º¸°í¼ÀÔ´Ï´Ù. º» º¸°í¼´Â ¿¬±¸ ¸ñÀû°ú ½ÃÀå ³» ÁÖ¿ä °ø±Þ¾÷ü ¹× À¯Åë¾÷ü, Á¦Ç° ½ÂÀÎ °ü·Ã ±ÔÁ¦ ȯ°æ¿¡ ´ëÇÑ »ó¼¼ÇÑ ¼³¸íÀ» Á¦°øÇÕ´Ï´Ù.
µ¶ÇØ ÆíÀǼºÀ» À§ÇØ º¸°í¼´Â À庰 ±¸¼ºÀ¸·Î Æí¼ºµÇ¾úÀ¸¸ç, °¢ ºÎºÐÀº ¼Ò´ÜÀ§·Î ¼¼ºÐȵǾú½À´Ï´Ù. º¸°í¼´Â ÀûÀýÈ÷ ¹èÄ¡µÈ ¹æ´ëÇÑ ±×·¡ÇÁ ¹× Ç¥¸¦ Æ÷ÇÔÇÕ´Ï´Ù. ÁÖ¿ä ºÎ¹®ÀÇ ½ÇÁ¦ ¹× ¿¹»ó °ªÀ» ½Ã°¢ÀûÀ¸·Î Ç¥ÇöÇÑ ³»¿ëÀº µ¶ÀÚ¿¡°Ô ½Ã°¢Àû ¸Å·ÂÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ´Â ¶ÇÇÑ °ú°Å¿Í ¿¹Ãø ±â°£ ¸» ½ÃÁ¡ÀÇ ÁÖ¿ä ºÎ¹® ½ÃÀå Á¡À¯À² ºñ±³¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.
º» º¸°í¼¿¡¼´Â ¼¼°èÀÇ ¾È°ú ÀǾàǰ ½ÃÀåÀ» Á¦Ç°, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªº°·Î ºÐ¼®Çß½À´Ï´Ù. °¢ ±âÁغ° ÁÖ¿ä ºÎ¹®À» ½ÉÃþ ¿¬±¸ÇÏ¿´À¸¸ç, 2035³â ¸» ±âÁØ °¢ ºÎ¹®ÀÇ ½ÃÀå Á¡À¯À²À» Á¦½ÃÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °¡Ä¡ ÀÖ´Â ÀλçÀÌÆ®´Â ½ÃÀå °ü°èÀÚµéÀÌ ¼¼°èÀÇ ¾È°ú ÀǾàǰ ½ÃÀå¿¡ ´ëÇÑ ÅõÀÚ °áÁ¤À» ³»¸®´Â µ¥ À¯¿ëÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå ÀüÁ¦Á¶°Ç°ú Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à : ¼¼°è ½ÃÀå
Á¦4Àå ½ÃÀå °³¿ä
¼Ò°³
°³¿ä
½ÃÀå ¿ªÇÐ
¼¼°èÀÇ ¾È°ú ÀǾàǰ ½ÃÀå ºÐ¼®°ú ¿¹Ãø(2020-2035³â)
Á¦5Àå ÁÖ¿ä ÀλçÀÌÆ®
ÁÖ¿ä Áö¿ª ¹× ±¹°¡ ÀÇ·áºñ ÁöÃâ
¾È°ú ÀǾàǰÀÇ ÃÖ±Ù Áøº¸
ÁÖ¿ä Áö¿ª ¹× ±¹°¡¿¡ ÀÖ¾î¼ÀÇ ¾ÈÁúȯÀÇ ¿ªÇÐ
¾È°ú ÀǾàǰÀÇ °¡°Ý µ¿Çâ
ÁÖ¿ä Áö¿ª ¹× ±¹°¡ ±ÔÁ¦ ½Ã³ª¸®¿À
Porter's Five Forces ºÐ¼®
PESTEL ºÐ¼®
¹ë·ùüÀÎ ºÐ¼®
ÃÖÁ¾ »ç¿ëÀÚ¸¦ À§ÇÑ ÁÖ¿ä ±¸¸Å ÁöÇ¥
½Å±Ô ½ÃÀå Âü°¡ÀÚ¸¦ À§ÇÑ ½ÃÀå °³Ã´ Àü·«
ÁÖ¿ä ¾÷°è À̺¥Æ®(ÆÄÆ®³Ê½Ê, Äݶ󺸷¹À̼Ç, Á¦Ç° ½ÂÀÎ, ÇÕº´ ¹× Àμö)
ÁÖ¿ä °æÀïÀÌ Á¦°øÇÏ´Â ÁÖ¿ä Á¦Ç° º¥Ä¡ ¸¶Å©
Á¦6Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ¾àÁ¦ À¯Çüº°
¼Ò°³ ¹× Á¤ÀÇ
ÁÖ¿ä Á¶»ç °á°ú ¹× ÁøÀü
½ÃÀå ¸ÅÃâ ¿¹Ãø : ¾àÁ¦ À¯Çüº°(2020-2035³â)
Ç׾˷¹¸£±âÁ¦
Ç×°¨¿°Á¦
ºñ½ºÅ×·ÎÀ̵åÁ¦
Ç×VEGF ÀǾàǰ
¾ÛŸ¸Ó
Ç×ü(´ÜÀÏŬ·ÐÇ×ü ¹× ÀÌÁ߯¯À̼º Ç×ü)
À¶ÇÕ ´Ü¹éÁú
À¯ÀüÀÚ Ä¡·áÁ¦
±âŸ
½ÃÀåÀÇ ¸Å·Â : ¾àÁ¦ À¯Çüº°
Á¦7Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Åõ¿© °æ·Îº°
¼Ò°³ ¹× Á¤ÀÇ
ÁÖ¿ä Á¶»ç °á°ú ¹× ÁøÀü
½ÃÀå ¸ÅÃâ ¿¹Ãø : Åõ¿© °æ·Îº°(2020-2035³â)
½ÃÀåÀÇ ¸Å·Â : Åõ¿© °æ·Îº°
Á¦8Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Á¦Çüº°
¼Ò°³ ¹× Á¤ÀÇ
ÁÖ¿ä Á¶»ç °á°ú ¹× ÁøÀü
½ÃÀå ¸ÅÃâ ¿¹Ãø : Á¦Çüº°(2020-2035³â)
Á©
Á¡¾È¾×
¿¬°í
ÇöŹ¾× ¹× ¿ë¾×
±âŸ
½ÃÀåÀÇ ¸Å·Â : Á¦Çüº°
Á¦9Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Á¦Ç° À¯Çüº°
¼Ò°³ ¹× Á¤ÀÇ
ÁÖ¿ä Á¶»ç °á°ú ¹× ÁøÀü
½ÃÀå ¸ÅÃâ ¿¹Ãø : Á¦Ç° À¯Çüº°(2020-2035³â)
½ÃÀåÀÇ ¸Å·Â : Á¦Ç° À¯Çüº°
Á¦10Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ÀûÀÀÁõº°
¼Ò°³ ¹× Á¤ÀÇ
ÁÖ¿ä Á¶»ç °á°ú ¹× ÁøÀü
½ÃÀå ¸ÅÃâ ¿¹Ãø : ÀûÀÀÁõº°(2020-2035³â)
³ì³»Àå
¾È±¸°ÇÁ¶Áõ
³ëÈ È²¹Ý º¯¼ºÁõ
´ç´¢º´ ¸Á¸·Áõ
°á¸·¿°
¹é³»Àå
¸Á¸· ¹Ú¸®
±âŸ
½ÃÀåÀÇ ¸Å·Â : ÀûÀÀÁõº°
Á¦11Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : À¯Åë ä³Îº°
¼Ò°³ ¹× Á¤ÀÇ
ÁÖ¿ä Á¶»ç °á°ú ¹× ÁøÀü
½ÃÀå ¸ÅÃâ ¿¹Ãø : À¯Åë ä³Îº°(2020-2035³â)
º´¿ø ¾à±¹
¼Ò¸Å ¾à±¹
¿Â¶óÀÎ ¾à±¹
½ÃÀåÀÇ ¸Å·Â : À¯Åë ä³Îº°
Á¦12Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°
ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ¸ÅÃâ ¿¹Ãø : Áö¿ªº°
ºÏ¹Ì
À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
½ÃÀåÀÇ ¸Å·Â : Áö¿ªº°
Á¦13Àå ºÏ¹Ì ½ÃÀå ºÐ¼®°ú ¿¹Ãø
Á¦14Àå À¯·´ ½ÃÀå ºÐ¼®°ú ¿¹Ãø
µ¶ÀÏ
¿µ±¹
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
½ºÀ§½º
³×´ú¶õµå
±âŸ À¯·´
Á¦15Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ºÐ¼®°ú ¿¹Ãø
Áß±¹
Àεµ
ÀϺ»
Çѱ¹
È£ÁÖ ¹× ´ºÁú·£µå
±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
Á¦16Àå ¶óÆ¾¾Æ¸Þ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø
ºê¶óÁú
¸ß½ÃÄÚ
¾Æ¸£ÇîÆ¼³ª
±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
Á¦17Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø
GCC ±¹°¡
³²¾ÆÇÁ¸®Ä«
±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦18Àå °æÀï ±¸µµ
½ÃÀå ±â¾÷ : °æÀï ¸ÅÆ®¸¯½º(±â¾÷ µî±Þº°, ±Ô¸ðº°)
½ÃÀå Á¡À¯À² ºÐ¼®±â¾÷º°(2024³â)
±â¾÷ ÇÁ·ÎÆÄÀÏ
Alcon Inc.
Novartis AG
Bausch Lomb.
Merck & Co., Inc.
Regeneron Pharmaceuticals Inc.
Coherus BioSciences, Inc.
Pfizer Inc.
AbbVie
RIBOMIC
Santen Pharmaceutical Co., Ltd.
Cipla Limited
Lupin Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.
Novaliq GmbH
ZEXUS PHARMA
Grevis Pharmaceuticals Pvt. Ltd.
HBR
Ophthalmic Drugs Market- Scope of Report
TMR's report on the global Ophthalmic Drugs Marketstudies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Ophthalmic Drugs Marketfor the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Ophthalmic Drugs Marketfrom 2025 to 2035.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Ophthalmic Drugs Market .
Market Snapshot
Market Value in 2024 US$ 35.4 Bn
Market Value in 2035 US$ 67.9 Bn
CAGR 6.1%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Ophthalmic Drugs Market .
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Ophthalmic Drugs Market . These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Ophthalmic Drugs Market .
The report delves into the competitive landscape of the global Ophthalmic Drugs Market . Key players operating in the global Ophthalmic Drugs Markethave been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Ophthalmic Drugs Marketprofiled in this report.
Key Questions Answered in Global Ophthalmic Drugs MarketReport:
What are the opportunities in the global Ophthalmic Drugs Market ?
What are the major drivers, restraints, opportunities, and threats in the Market ?
Which regional Market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the Market positions of different companies operating in the global Market ?
Ophthalmic Drugs Market- Research Objectives and Research Approach
The comprehensive report on the global Ophthalmic Drugs Marketbegins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Ophthalmic Drugs Marketin terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Ophthalmic Drugs Market .
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ophthalmic Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ophthalmic Drugs Market Analysis and Forecasts, 2020 to 2035
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Healthcare Expenditure across Key Regions / Countries
5.2. Recent Advancements in Ophthalmic Medications
5.3. Epidemiology of Ophthalmic Disorders across Key Regions / Countries
5.4. Pricing Trends for Ophthalmic Drugs
5.5. Regulatory Scenario across Key Regions / Countries
5.6. PORTER's Five Forces Analysis
5.7. PESTEL Analysis
5.8. Value Chain Analysis
5.9. Key Purchase Metrics for End-users
5.10. Go-to-Market Strategy for New Market Entrants
5.11. Key Industry Events (Partnerships, Collaborations, Product approvals, mergers & acquisitions)
5.12. Benchmarking of Key Products Offered by the Leading Competitors
6. Global Ophthalmic Drugs Market Analysis and Forecasts, By Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Type, 2020 to 2035
6.3.1. Anti-Allergy Drugs
6.3.2. Anti-infective Drugs
6.3.3. Nonsteroidal Drugs
6.3.4. Anti-VEGF Drugs
6.3.4.1. Aptamer
6.3.4.2. Antibodies (mAb & Bispecific Antibody)
6.3.4.3. Fusion Protein
6.3.5. Gene Therapy Drugs
6.3.6. Others
6.4. Market Attractiveness By Drug Type
7. Global Ophthalmic Drugs Market Analysis and Forecasts, By Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Route of Administration, 2020 to 2035
7.3.1. Topical
7.3.2. Intraocular
7.3.3. Others
7.4. Market Attractiveness By Route of Administration
8. Global Ophthalmic Drugs Market Analysis and Forecasts, By Dosage Form
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Dosage Form, 2020 to 2035
8.3.1. Gel
8.3.2. Drop
8.3.3. Ointment
8.3.4. Suspension & Solutions
8.3.5. Others
8.4. Market Attractiveness By Dosage Form
9. Global Ophthalmic Drugs Market Analysis and Forecasts, By Product Type
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Product Type, 2020 to 2035
9.3.1. Prescription Drugs
9.3.2. Over-the-Counter
9.4. Market Attractiveness By Product Type
10. Global Ophthalmic Drugs Market Analysis and Forecasts, By Indication
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By Indication, 2020 to 2035
10.3.1. Glaucoma
10.3.2. Dry Eye Disease
10.3.3. Age-Related Macular Degeneration
10.3.4. Diabetic Retinopathy
10.3.5. Pink Eye
10.3.6. Cataracts
10.3.7. Retinal Detachment
10.3.8. Others
10.4. Market Attractiveness By Indication
11. Global Ophthalmic Drugs Market Analysis and Forecasts, By Distribution Channel
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Market Value Forecast By Distribution Channel, 2020 to 2035
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Attractiveness By Distribution Channel
12. Global Ophthalmic Drugs Market Analysis and Forecasts, By Region
12.1. Key Findings
12.2. Market Value Forecast By Region
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness By Region
13. North America Ophthalmic Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast By Drug Type, 2020 to 2035
13.2.1. Anti-Allergy Drugs
13.2.2. Anti-infective Drugs
13.2.3. Nonsteroidal Drugs
13.2.4. Anti-VEGF Drugs
13.2.4.1. Aptamer
13.2.4.2. Antibodies (mAb & Bispecific Antibody)
13.2.4.3. Fusion Protein
13.2.5. Gene Therapy Drugs
13.2.6. Others
13.3. Market Value Forecast By Route of Administration, 2020 to 2035
13.3.1. Topical
13.3.2. Intraocular
13.3.3. Others
13.4. Market Value Forecast By Dosage Form, 2020 to 2035
13.4.1. Gel
13.4.2. Drop
13.4.3. Ointment
13.4.4. Suspension & Solutions
13.4.5. Others
13.5. Market Value Forecast By Product Type, 2020 to 2035
13.5.1. Prescription Drugs
13.5.2. Over-the-Counter
13.6. Market Value Forecast By Indication, 2020 to 2035
13.6.1. Glaucoma
13.6.2. Dry Eye Disease
13.6.3. Age-Related Macular Degeneration
13.6.4. Diabetic Retinopathy
13.6.5. Pink Eye
13.6.6. Cataracts
13.6.7. Retinal Detachment
13.6.8. Others
13.7. Market Value Forecast By Distribution Channel, 2020 to 2035
13.7.1. Hospital Pharmacies
13.7.2. Retail Pharmacies
13.7.3. Online Pharmacies
13.8. Market Value Forecast By Country , 2020 to 2035
13.8.1. U.S.
13.8.2. Canada
13.9. Market Attractiveness Analysis
13.9.1. By Drug Type
13.9.2. By Route of Administration
13.9.3. By Dosage Form
13.9.4. By Product Type
13.9.5. By Indication
13.9.6. By Distribution Channel
13.9.7. By Country
14. Europe Ophthalmic Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Market Value Forecast By Drug Type, 2020 to 2035
14.2.1. Anti-Allergy Drugs
14.2.2. Anti-infective Drugs
14.2.3. Nonsteroidal Drugs
14.2.4. Anti-VEGF Drugs
14.2.4.1. Aptamer
14.2.4.2. Antibodies (mAb & Bispecific Antibody)
14.2.4.3. Fusion Protein
14.2.5. Gene Therapy Drugs
14.2.6. Others
14.3. Market Value Forecast By Route of Administration, 2020 to 2035
14.3.1. Topical
14.3.2. Intraocular
14.3.3. Others
14.4. Market Value Forecast By Dosage Form, 2020 to 2035
14.4.1. Gel
14.4.2. Drop
14.4.3. Ointment
14.4.4. Suspension & Solutions
14.4.5. Others
14.5. Market Value Forecast By Product Type, 2020 to 2035
14.5.1. Prescription Drugs
14.5.2. Over-the-Counter
14.6. Market Value Forecast By Indication, 2020 to 2035
14.6.1. Glaucoma
14.6.2. Dry Eye Disease
14.6.3. Age-Related Macular Degeneration
14.6.4. Diabetic Retinopathy
14.6.5. Pink Eye
14.6.6. Cataracts
14.6.7. Retinal Detachment
14.6.8. Others
14.7. Market Value Forecast By Distribution Channel, 2020 to 2035
14.7.1. Hospital Pharmacies
14.7.2. Retail Pharmacies
14.7.3. Online Pharmacies
14.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
14.8.1. Germany
14.8.2. UK
14.8.3. France
14.8.4. Italy
14.8.5. Spain
14.8.6. Switzerland
14.8.7. The Netherlands
14.8.8. Rest of Europe
14.9. Market Attractiveness Analysis
14.9.1. By Drug Type
14.9.2. By Route of Administration
14.9.3. By Dosage Form
14.9.4. By Product Type
14.9.5. By Indication
14.9.6. By Distribution Channel
14.9.7. By Country / Sub-region
15. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast
15.1. Introduction
15.2. Market Value Forecast By Drug Type, 2020 to 2035
15.2.1. Anti-Allergy Drugs
15.2.2. Anti-infective Drugs
15.2.3. Nonsteroidal Drugs
15.2.4. Anti-VEGF Drugs
15.2.4.1. Aptamer
15.2.4.2. Antibodies (mAb & Bispecific Antibody)
15.2.4.3. Fusion Protein
15.2.5. Gene Therapy Drugs
15.2.6. Others
15.3. Market Value Forecast By Route of Administration, 2020 to 2035
15.3.1. Topical
15.3.2. Intraocular
15.3.3. Others
15.4. Market Value Forecast By Dosage Form, 2020 to 2035
15.4.1. Gel
15.4.2. Drop
15.4.3. Ointment
15.4.4. Suspension & Solutions
15.4.5. Others
15.5. Market Value Forecast By Product Type, 2020 to 2035
15.5.1. Prescription Drugs
15.5.2. Over-the-Counter
15.6. Market Value Forecast By Indication, 2020 to 2035
15.6.1. Glaucoma
15.6.2. Dry Eye Disease
15.6.3. Age-Related Macular Degeneration
15.6.4. Diabetic Retinopathy
15.6.5. Pink Eye
15.6.6. Cataracts
15.6.7. Retinal Detachment
15.6.8. Others
15.7. Market Value Forecast By Distribution Channel, 2020 to 2035
15.7.1. Hospital Pharmacies
15.7.2. Retail Pharmacies
15.7.3. Online Pharmacies
15.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
15.8.1. China
15.8.2. India
15.8.3. Japan
15.8.4. South Korea
15.8.5. Australia & New Zealand
15.8.6. Rest of Asia Pacific
15.9. Market Attractiveness Analysis
15.9.1. By Drug Type
15.9.2. By Route of Administration
15.9.3. By Dosage Form
15.9.4. By Product Type
15.9.5. By Indication
15.9.6. By Distribution Channel
15.9.7. By Country / Sub-region
16. Latin America Ophthalmic Drugs Market Analysis and Forecast
16.1. Introduction
16.2. Market Value Forecast By Drug Type, 2020 to 2035
16.2.1. Anti-Allergy Drugs
16.2.2. Anti-infective Drugs
16.2.3. Nonsteroidal Drugs
16.2.4. Anti-VEGF Drugs
16.2.4.1. Aptamer
16.2.4.2. Antibodies (mAb & Bispecific Antibody)
16.2.4.3. Fusion Protein
16.2.5. Gene Therapy Drugs
16.2.6. Others
16.3. Market Value Forecast By Route of Administration, 2020 to 2035
16.3.1. Topical
16.3.2. Intraocular
16.3.3. Others
16.4. Market Value Forecast By Dosage Form, 2020 to 2035
16.4.1. Gel
16.4.2. Drop
16.4.3. Ointment
16.4.4. Suspension & Solutions
16.4.5. Others
16.5. Market Value Forecast By Product Type, 2020 to 2035
16.5.1. Prescription Drugs
16.5.2. Over-the-Counter
16.6. Market Value Forecast By Indication, 2020 to 2035
16.6.1. Glaucoma
16.6.2. Dry Eye Disease
16.6.3. Age-Related Macular Degeneration
16.6.4. Diabetic Retinopathy
16.6.5. Pink Eye
16.6.6. Cataracts
16.6.7. Retinal Detachment
16.6.8. Others
16.7. Market Value Forecast By Distribution Channel, 2020 to 2035
16.7.1. Hospital Pharmacies
16.7.2. Retail Pharmacies
16.7.3. Online Pharmacies
16.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
16.8.1. Brazil
16.8.2. Mexico
16.8.3. Argentina
16.8.4. Rest of Latin America
16.9. Market Attractiveness Analysis
16.9.1. By Drug Type
16.9.2. By Route of Administration
16.9.3. By Dosage Form
16.9.4. By Product Type
16.9.5. By Indication
16.9.6. By Distribution Channel
16.9.7. By Country / Sub-region
17. Middle East & Africa Ophthalmic Drugs Market Analysis and Forecast
17.1. Introduction
17.2. Market Value Forecast By Drug Type, 2020 to 2035
17.2.1. Anti-Allergy Drugs
17.2.2. Anti-infective Drugs
17.2.3. Nonsteroidal Drugs
17.2.4. Anti-VEGF Drugs
17.2.4.1. Aptamer
17.2.4.2. Antibodies (mAb & Bispecific Antibody)
17.2.4.3. Fusion Protein
17.2.5. Gene Therapy Drugs
17.2.6. Others
17.3. Market Value Forecast By Route of Administration, 2020 to 2035
17.3.1. Topical
17.3.2. Intraocular
17.3.3. Others
17.4. Market Value Forecast By Dosage Form, 2020 to 2035
17.4.1. Gel
17.4.2. Drop
17.4.3. Ointment
17.4.4. Suspension & Solutions
17.4.5. Others
17.5. Market Value Forecast By Product Type, 2020 to 2035
17.5.1. Prescription Drugs
17.5.2. Over-the-Counter
17.6. Market Value Forecast By Indication, 2020 to 2035
17.6.1. Glaucoma
17.6.2. Dry Eye Disease
17.6.3. Age-Related Macular Degeneration
17.6.4. Diabetic Retinopathy
17.6.5. Pink Eye
17.6.6. Cataracts
17.6.7. Retinal Detachment
17.6.8. Others
17.7. Market Value Forecast By Distribution Channel, 2020 to 2035
17.7.1. Hospital Pharmacies
17.7.2. Retail Pharmacies
17.7.3. Online Pharmacies
17.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
17.8.1. GCC Countries
17.8.2. South Africa
17.8.3. Rest of Middle East & Africa
17.9. Market Attractiveness Analysis
17.9.1. By Drug Type
17.9.2. By Route of Administration
17.9.3. By Dosage Form
17.9.4. By Product Type
17.9.5. By Indication
17.9.6. By Distribution Channel
17.9.7. By Country / Sub-region
18. Competition Landscape
18.1. Market Player - Competition Matrix (By Tier and Size of companies)
18.2. Market Share Analysis By Company (2024)
18.3. Company Profiles
18.3.1. Alcon Inc.
18.3.1.1. Company Overview
18.3.1.2. Financial Overview
18.3.1.3. Product Portfolio
18.3.1.4. Business Strategies
18.3.1.5. Recent Developments
18.3.2. Novartis AG
18.3.2.1. Company Overview
18.3.2.2. Financial Overview
18.3.2.3. Product Portfolio
18.3.2.4. Business Strategies
18.3.2.5. Recent Developments
18.3.3. Bausch + Lomb.
18.3.3.1. Company Overview
18.3.3.2. Financial Overview
18.3.3.3. Product Portfolio
18.3.3.4. Business Strategies
18.3.3.5. Recent Developments
18.3.4. Merck & Co., Inc.
18.3.4.1. Company Overview
18.3.4.2. Financial Overview
18.3.4.3. Product Portfolio
18.3.4.4. Business Strategies
18.3.4.5. Recent Developments
18.3.5. Regeneron Pharmaceuticals Inc.
18.3.5.1. Company Overview
18.3.5.2. Financial Overview
18.3.5.3. Product Portfolio
18.3.5.4. Business Strategies
18.3.5.5. Recent Developments
18.3.6. Coherus BioSciences, Inc.
18.3.6.1. Company Overview
18.3.6.2. Financial Overview
18.3.6.3. Product Portfolio
18.3.6.4. Business Strategies
18.3.6.5. Recent Developments
18.3.7. Pfizer Inc.
18.3.7.1. Company Overview
18.3.7.2. Financial Overview
18.3.7.3. Product Portfolio
18.3.7.4. Business Strategies
18.3.7.5. Recent Developments
18.3.8. AbbVie
18.3.8.1. Company Overview
18.3.8.2. Financial Overview
18.3.8.3. Product Portfolio
18.3.8.4. Business Strategies
18.3.8.5. Recent Developments
18.3.9. RIBOMIC
18.3.9.1. Company Overview
18.3.9.2. Financial Overview
18.3.9.3. Product Portfolio
18.3.9.4. Business Strategies
18.3.9.5. Recent Developments
18.3.10. Santen Pharmaceutical Co., Ltd.
18.3.10.1. Company Overview
18.3.10.2. Financial Overview
18.3.10.3. Product Portfolio
18.3.10.4. Business Strategies
18.3.10.5. Recent Developments
18.3.11. Cipla Limited
18.3.11.1. Company Overview
18.3.11.2. Financial Overview
18.3.11.3. Product Portfolio
18.3.11.4. Business Strategies
18.3.11.5. Recent Developments
18.3.12. Lupin Pharmaceuticals, Inc.
18.3.12.1. Company Overview
18.3.12.2. Financial Overview
18.3.12.3. Product Portfolio
18.3.12.4. Business Strategies
18.3.12.5. Recent Developments
18.3.13. Ocular Therapeutix, Inc.
18.3.13.1. Company Overview
18.3.13.2. Financial Overview
18.3.13.3. Product Portfolio
18.3.13.4. Business Strategies
18.3.13.5. Recent Developments
18.3.14. Novaliq GmbH
18.3.14.1. Company Overview
18.3.14.2. Financial Overview
18.3.14.3. Product Portfolio
18.3.14.4. Business Strategies
18.3.14.5. Recent Developments
18.3.15. ZEXUS PHARMA
18.3.15.1. Company Overview
18.3.15.2. Financial Overview
18.3.15.3. Product Portfolio
18.3.15.4. Business Strategies
18.3.15.5. Recent Developments
18.3.16. Grevis Pharmaceuticals Pvt. Ltd.
18.3.16.1. Company Overview
18.3.16.2. Financial Overview
18.3.16.3. Product Portfolio
18.3.16.4. Business Strategies
18.3.16.5. Recent Developments